Compare Ares Capital Corporation (ARCC) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs 22nd Century Group Inc — how do they compare? Ares Capital Corporation trades at $19.89 (market cap $14.34B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Ares Capital Corporation is far larger — about 9434.2× 22nd Century Group Inc's market cap, and Ares Capital Corporation pays a 9.61% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| ARCC | XXII | |
|---|---|---|
Market Cap | $14.34B | $1.52M |
Sector | Financials | Technology |
52-Week High | $22.68 | $801.00 |
52-Week Low | $17.45 | $3.72 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.87, down 0.55% with a bullish technical outlook supported by moving averages. The company reported $1.51B revenue and $1.30B net income for 2025, maintaining an 86.25% profit margin. Recent earnings show slight misses against expectations, but dividend coverage remains stable at 104% with a 9.9% yield. Analyst consensus is strongly bullish with 24 buy ratings and a $19.63 price target.
The stock presents income appeal with its high dividend yield and stable payout history, though recent earnings compression and rising non-accruals to 2.4% signal credit quality concerns. Private credit sector strain and potential rate cuts pose medium-term risks to net investment income, which is 71% variable-rate exposed.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
